18 January 2023 - Nirsevimab is the first investigational long-acting antibody designed for all infants to help protect against respiratory syncytial virus (RSV) throughout their first RSV season with a single dose.

Health Canada has accepted a new drug submission for nirsevimab, the first investigational single dose long-acting antibody designed for all infants to help protect against medically attended lower respiratory tract infections throughout their first respiratory syncytial virus season. Nirsevimab is being developed by Sanofi and AstraZeneca.

Read Sanofi press release